Management of patients with biochemical recurrence after local therapy for prostate cancer

Research output: Contribution to journalArticle

Abstract

Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

Original languageEnglish (US)
Pages (from-to)1205-1219
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume27
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Prostate-Specific Antigen
Androgens
Prostatic Neoplasms
Recurrence
Prostatectomy
Comorbidity
Radiotherapy
Therapeutics

Keywords

  • Androgen-deprivation therapy
  • Biochemical recurrence
  • Hormonal therapy
  • Prostate cancer
  • Rising prostate-specific antigen

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{9d448ebf411845bbad37928ab3dd7d76,
title = "Management of patients with biochemical recurrence after local therapy for prostate cancer",
abstract = "Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.",
keywords = "Androgen-deprivation therapy, Biochemical recurrence, Hormonal therapy, Prostate cancer, Rising prostate-specific antigen",
author = "Channing Paller and Emmanuel Antonarakis and Mario Eisenberger and Carducci, {Michael A}",
year = "2013",
month = "12",
doi = "10.1016/j.hoc.2013.08.005",
language = "English (US)",
volume = "27",
pages = "1205--1219",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Management of patients with biochemical recurrence after local therapy for prostate cancer

AU - Paller, Channing

AU - Antonarakis, Emmanuel

AU - Eisenberger, Mario

AU - Carducci, Michael A

PY - 2013/12

Y1 - 2013/12

N2 - Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

AB - Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

KW - Androgen-deprivation therapy

KW - Biochemical recurrence

KW - Hormonal therapy

KW - Prostate cancer

KW - Rising prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84887016282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887016282&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.08.005

DO - 10.1016/j.hoc.2013.08.005

M3 - Article

VL - 27

SP - 1205

EP - 1219

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -